This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pathologists, and other healthcare providers involved and/or interested in the management of patients with breast cancer.

8.00 PM	Welcome, introduction, and demographic questions Larry Norton, MD Martine Piccart-Gebhart, MD, PhD
8.05 PM	Is personalized therapy for breast cancer a reality in 2010?
8.25 PM	Bone-targeted therapies: Will they be a major addition to adjuvant therapy?
8.45 PM	Triple-negative breast cancer: How can we identify the target?
9.05 PM	Chemotherapy-resistant breast cancer: What’s next, doctor?
9.25 PM	HER2-postive breast cancer: How can we fine tune our approach?
9.45 PM	Audience input/questions and concluding remarks Larry Norton, MD Martine Piccart-Gebhart, MD, PhD
10.00 PM	Adjourn

Upon completion of this educational activity, participants should be able to:

• Identify both the current and emerging roles of gene expression profiles in treatment planning for patients with breast cancer
• Assess the utility of bone-targeted agents in the adjuvant treatment of breast cancer
• Discuss clinical challenges in the management of triple-negative breast cancer, and review recent advances in this setting
• Evaluate strategies to overcome chemotherapy resistance in patients with metastatic breast cancer, and select therapeutic agents for use in this patient population
• Describe recent clinical trials evaluating emerging and currently available targeted therapies for patients with HER2-positive breast cancer

In accordance with the ACCME Essentials and Standards, everyone involved in planning or presenting this educational activity will be required to disclose any relevant financial relationships with commercial interests in the healthcare industry, and this information will be made available to participants at the start of the activity. In addition, speakers who incorporate information about off-label or investigational use of drugs or devices are required to disclose that information at the beginning of their presentation.

This educational activity may contain discussion of published or and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The sponsors and supporters of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the sponsors and supporters of this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you require reasonable accommodations for a disability in order to participate fully in this continuing education activity, please contact Kimberly Friese at +1 678 892 1364 prior to the live event.